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Abst rac t
Introduction: In clinical practice, reliable tools for monitoring specific immunotherapy (SIT) are of utmost impor-
tance. 
Aim: To assess the usefulness of the basophil activation test (BAT) in monitoring SIT in paediatric patients with 
allergy to house dust mites (HDM).
Material and methods: Thirty-one children qualified for SIT with HDM, of whom 21 completed the SIT during the 
observation period. The BAT was carried out prior to commencing the SIT (time point BAT1) and upon finishing the 
initial pack of allergy vaccine (cumulative dose of allergen 12487.5 PNU; BAT2), as well as after the second vac-
cine pack (cumulative dose of allergen 23750.0 PNU; BAT3). Peripheral blood of the patients was stimulated with 
allergen solutions in five concentrations from 0.00225 ng/ml to 22.5 ng/ml. Basophil activation was measured by 
CD63 expression in flow cytometry.
Results: For the allergen concentration of 0.225 ng/ml, a statistically significant decrease in median basophil ac-
tivation was observed, from 51.29% at BAT1 to 8.48% at BAT2 (p = 0.004) and 4.21% at BAT3 (p < 0.001). For the 
allergen concentration of 0.0225 ng/ml, a statistically significant decrease was seen between BAT1 (1.72%) and 
BAT3 (0.21%, p = 0.01). Median CD-sens index decreased significantly from 1099.02 at BAT1 to 179.31 at BAT2  
(p < 0.002) and 168.04 at BAT3 (p < 0.001).
Conclusions: There is a significant decrease in BAT results in the course of specific immunotherapy with HDM al-
lergens in children, with the optimum allergen concentration for monitoring basophil response at 0.225 ng/ml. The 
CD-sens index seems to be a better monitoring parameter than the plain percentage of CD63-expressing basophils.
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Introduction
Allergic symptoms may be alleviated with medica-
tions; however, only specific immunotherapy (SIT) con-
stitutes a causal treatment of atopic diseases. The SIT 
may interrupt the “allergic march” and cause clinical im-
provement to persist years after cessation of the treat-
ment [1]. Unfortunately, providing a univocal answer to 
the question of the optimum duration of immunotherapy 
in a given patient proves difficult in clinical conditions. 
The clinical effectiveness of SIT seems to be related to 
the administered dose of allergen, rather than merely 
the duration of the therapy; therefore, assessing the 
therapeutic effects after administering defined cumula-
tive doses of allergen seems reasonable [2]. In practice, 
the time of administration of the same cumulative dose 
may vary substantially, which is due to individual toler-
ance and compliance, as well as complicating health 
conditions (e.g. infections). The role of basophils in the 
allergic reaction and in development of immunological 
tolerance during SIT has been studied intensively [3]. It 
is assumed that basophil stimulation in vitro replicates 
an in vivo mechanism that leads to the development of 
allergic symptoms. The SIT has been demonstrated to 
modulate basophil and mastocyte activation thresholds 
and decreases IgE-mediated histamine release [4, 5]. 
Studies into the course of immunotherapy demonstrated 
that SIT initially decreases basophil activation by the al-
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lergen with a subsequent decrease in basophil count and 
production of interleukin (IL)-4 and IL-13 [6]. The decrease 
in basophil activation as well as depletion of mediator 
reserves due to repetitive allergen stimulation is con-
sidered as the key mechanism at early stages of SIT [7]. 
Hence, a decrease in basophil activation in response to 
the allergen in vitro seems a promising marker of clinical 
tolerance developing during the course of SIT [8].
Despite basophil activation test (BAT) being consid-
ered as an aid in diagnosis of airborne allergy, drug aller-
gy, Hymenoptera venom allergy, and in autoimmune urti-
caria, as well as in qualification for SIT, the protocols used 
and results obtained still vary from centre to centre [9]. 
Basophil activation markers with proven sensitivity and 
specificity are CD63 and CD203c. CD63, i.e. lysosomal-
associated membrane glycoprotein-3, LAMP-3 in a rest-
ing basophil is located in the membrane of intracellular 
secretory granules. Upon FcεRI activation, it is expressed 
on the basophil surface [10]. CD203c to is a transmem-
branous, glycosylated molecule, which is constitutively 
present on basophil surfaces, and upon being activated 
by allergen its expression increases [11]. Both markers 
are characterised by similar sensitivity and specificity. 
CD63 is used more widely due to the direct connection 
between its membrane expression and basophil degran-
ulation [12, 13].
Two outcome measures of basophil activations are 
used: basophil reactivity, i.e. the number of basophils ac-
tivated by allergen, and basophil sensitivity, i.e. allergen 
concentration causing half of the basophils to degranu-
late. Basophil sensitivity provides additional information 
about the sensitivity to allergen – how much allergen 
basophils can tolerate before they react. On the curve 
of reactivity vs. allergen concentration, the eliciting con-
centration at which 50% of basophils respond (EC50) is 
determined. EC50 can be expressed as ‘CD-sens’ by in-
version and multiplication by 100. Basophil reactivity may 
be expressed as ‘CD-max’ (see below) [9].
Aim
The aim of the present study was to assess the use-
fulness of a BAT in monitoring SIT in paediatric patients 
with allergy to house dust mites (HDM).
Material and methods
Study protocol 
During the first stage of the study conducted in the 
years 2010–2012, the results of which were published 
elsewhere [14], out of the group of 52 children with re-
spiratory allergy aged 7–18 years, 31 had been qualified 
for SIT with HDM allergens based on the clinical symp-
toms, skin prick tests (SPT) results, and sIgE concentra-
tion. The first basophil activation test (BAT1) was carried 
out in those patients before commencing SIT. Control 
BATs were performed after administering to the subjects 
defined cumulative doses of the allergen – respectively 
12487.5 PNU (the total allergen amount in the initial pack 
of allergy vaccines; measuring point (BAT2)) and 23750.0 
PNU (cumulative dose from the first and second packs of 
the vaccine (BAT3)). Figure 1 presents the study design. 
Changes in two parameters of basophil activation 
upon stimulation were analysed during the SIT. The first 
was calculated by subtracting the baseline basophil ac-
tivation recorded in the negative control from the maxi-
mum activation after stimulation with the allergen at 
defined concentrations. The second parameter – the CD-
sens used to describe subjects’ sensitivity to the allergen 
– was calculated by reversing the allergen concentration 
required to cause CD63 expression on 50% of all baso-
phils in the sample and multiplying the product by 100 
[15]. The study project was approved by the Committee 
of Bioethics of the Jagiellonian University; opinion no.: 
KBET/119/B/2011 of 1 July 2011. Written informed consent 
was obtained for each participant from a parent.
Basophil activation test 
Patients’ blood (each 400 μl) was collected in test 
tubes containing ethylenediaminetetraacetic acid (EDTA) 
before commencing SIT (BAT1), after completing the ini-
tial pack of allergy vaccine (BAT2), as well as after com-
pleting the second pack (BAT3). The test was performed 
within 2 h after the blood collection. The assessment of 
basophil activation by measuring CD63 antigen expres-
sion was carried out by means of the Flow2 CAST test 
(Bühlmann Laboratories AG, Schönenbuch, Switzerland). 
Anti-FcεRI monoclonal antibodies and fMLP oligopeptides 
were used as a positive control, while an unstimulated 
Figure 1. Design of the study. The BAT, SPT, and sIgE were 
carried out prior to commencing the SIT (BAT1) and after 
completing the initial pack (BAT2; cumulative allergen dose 
12487.5 PNU), and after completing two packages (BAT3; 
cumulative allergen dose 23750 PNU)
Qualification for the SIT with 
HDM allergens (SPT, sIgE)
BAT1
The first package of the vaccine 
(cumulative allergen dose 
12487.5 PNU)
The second package of the 
vaccine (cumulative allergen 
dose 23750.0 PNU)
SIT
SIT
BAT2
BAT3
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sample served as a negative control. Cells were stimu-
lated with an allergen of Dermatophagoides pteronys-
sinus (Dp) at the following concentrations: 22.5 ng/ml, 
2.25 ng/ml, 0.225 ng/ml, 0.0225 ng/ml, and 0.00225 ng/
ml. A mixture of FITC-conjugated anti-CD63 monoclonal 
antibodies, and PE-conjugated anti-CCR3 antibodies 
was added to the cellular suspension and incubated for 
15 min at 37°C, after which 2 ml of erythrocyte lysing 
solution were added, samples were centrifuged, resus-
pended in 0.3 ml of washing buffer, and analysed within 
1 h on a flow cytometer (FACSCalibur, Becton, Dickinson 
and Company, New Jersey, USA) with basophils gated as 
CCR3+/SSClow cells. 
Statistical analysis 
As the distribution of raw data was non-Gaussian, 
medians were used in the description of results and 
Wilcoxon’s test was applied in testing the statistical sig-
nificance of differences observed. The analysis was per-
formed using the GraphPad Prism 6 package.
Results
A total of 31 patients were qualified for the SIT; 
their results are presented in Table 1. Of these patients, 
21 subjects actually underwent the SIT, of whom 14 (67%) 
patients reported for the BAT2 testing 4 weeks after ad-
ministration of the last dose from the initial pack of the 
vaccine, and 21 (100%) patients reported for the BAT3 
carried out 4 weeks after administration of the last dose 
from the second pack of the vaccine. An overview of the 
results is shown in Figure 2. Significant changes were ob-
served for BAT results expressed as the percentage of ac-
tivated basophils at the allergen concentrations of 0.225 
ng/ml and 0.0225 ng/ml, as well as for CD-sens (Table 2). 
A comparison of indices that decreased significantly in 
the course of SIT is shown in Figure 3.
Discussion 
In our study, the BAT turned out to be a good objective 
parameter for the monitoring of SIT with an HDM aller-
gen in children. We applied a protocol measuring basophil 
activation in whole blood, used a CD63 as a basophil acti-
vation marker [14, 16–19], and measured SIT effects after 
having administered an earlier planned identical cumula-
tive dose of the allergen. In SIT monitoring, we used five 
10-fold allergen dilutions identified in the preliminary tests 
[20]. The basophil activation thus calculated decreased 
significantly in the second measurement for the concen-
tration of 0.225 ng/ml, and in the third for concentrations 
of 0.225 ng/ml and 0.0225 ng/ml respectively.
So far there have been few studies using a BAT to as-
sess SIT effectiveness in allergy to HDM. In the study by 
Ciepiela et al. basophil activation after stimulation with Dp 
or Dermatophagoides farinae (Df) or grass pollen allergens 
in 0.2 IR/ml concentration, decreased in the majority of 
children after a year of sublingual immunotherapy (SLIT) 
[21]. Sánchez and Cardona observed that basophil activa-
tion after Dp simulation in 1 ng/ml concentration is lower 
than in the control group after a year of the SIT with Dp/Df 
allergens in children with atopic dermatitis [22].
The BAT is more often applied in monitoring of immu-
notherapy for seasonal aeroallergens and Hymenoptera 
venom. Gokmen et al. for the olive pollen allergen con-
centration of 1 ng/ml obtained a decrease in basophil ac-
tivation after 7 preseasonal injections [23]. In the study 
Kepil Özdemir et al. basophil activation in response to 
stimulation with grass allergens in 4.5 × 10–4 and 4.5 × 
10–5 μg/ml concentrations decreased after the completed 
preseasonal immunotherapy and remained at a low level 
during the next grass pollination season [24]. Zitnik et al. 
demonstrated a decrease in CD63 expression output val-
ues in response to a submaximal concentration of 0.1 mg/
ml after 6 months of desensitisation to bee venom [25]. In 
a study by Ebo et al., after 6 months of venom immuno-
therapy (VIT), a decrease in basophil activation, also lim-
ited to a submaximal concentration of 0.01 mg/ml, was 
recorded, which, according to the authors, suggests that 
6 months of immunotherapy induces a decrease in a baso-
phil response, but not total suppression of these cells [26].
Not all researchers record decreases in basophil acti-
vation during immunotherapy. Van Overtvelt et al. did not 
observe significant changes in basophil activation despite 
the sIgG induction in patients receiving SLIT with grass 
pollens for 4 months [27]. Erdmann et al. did not observe 
a correlation between a change in basophil activation dur-
ing VIT and a response to a control sting provocation test. 
Unfortunately, basophil activation was performed with 
two allergen concentrations, 100 ng and 1 μg, and due to 
Table 1. Basophil activation test results in all 31 patients who were qualified for SIT
Basophil activation* Allergen concentration
22.5 ng/ml 2.25 ng/ml 0.225 ng/ml 0.0225 ng/ml 0.00225 ng/ml
Median 64.01% 67.49% 46.42% 4.87% –0.19%
Minimum 5.20% 1.80% –2.67% –5.48% –6.77%
Maximum 92.09% 89.10% 87.46% 52.32% 8.00%
*Basophil activation expressed as percent of basophils expressing CD63 on their surface in response to allergen, after subtracting the baseline activity (nega-
tive control).
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this fact the authors only assessed the changes in baso-
phil reactivity, but not basophil sensitivity, which may have 
resulted in obtaining false results [26, 28].
The latest publications emphasise that based on CD-
max, clinicians may draw erroneous conclusions pertain-
ing to continuation/cessation of a SIT or anti-IgE treat-
ment [29]. In assessing changes in basophil activation 
during immunotherapy, the CD-sens should be analysed 
[30–32]. In our study changes in CD-sens were signifi-
cant in all the subjects already at the first measurement 
during the SIT, while in the following determination we 
observed a further decrease in CD-sens. In the paediatric 
population, due to the lack of cooperation, it is frequently 
difficult to perform a specific provocation, constituting 
a gold standard in assessment of an allergen’s impact on 
the target organ, and, for this reason, application of a CD-
Figure 2. Overview of changes in basophil activation for each concentration (A – 22.5 ng/ml, B – 2.25 ng/ml, C – 0.225 
ng/ml, D – 0.0225 ng/ml, E – 0.00225 ng/ml) and changes in CD-sens (F) during the SIT. Horizontal lines indicate medians 
and ranges
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sens reflecting the sensitivity to an allergen is of pecu-
liar importance in this group. Our results correlated with 
a clinical improvement experienced by patients. Similar 
results were obtained by other authors in the case of SIT 
monitoring with birch and timothy as well as with Hyme-
noptera venom. In the study by Nopp et al. a decrease in 
CD-sens in the early stage of immunotherapy was accom-
panied by an increase in IgG4 antibody concentration 
and lack of changes in basophil reactivity [33]. Schmid 
et al. observed a decrease in basophil sensitivity already 
after 3 weeks, while Lalek et al. observed a decrease after 
two months of SIT, which correlated with a reduction in 
clinical symptoms [34, 35].
Conclusions
There is a significant decrease in BAT results in the 
course of specific immunotherapy with HDM allergens 
in children, with the optimum allergen concentration for 
monitoring the basophil response at 0.225 ng/ml. The 
CD-sens index seems a better monitoring parameter 
than the plain percentage of CD63-expressing basophils.
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